Clinical Commander

Back to dossier
ophtho.blepharitis-stye-chalazion.core.v1PRODUCTION
ophtho.blepharitis-stye-chalazion.core.v1

Blepharitis, hordeolum (stye), and chalazion

general_internal_medicinesubacutechronicadultpediatricgeriatric
Hard-required inputs
0 / 6
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Frame as a three-disorder common-outpatient bundle (blepharitis / stye / chalazion) sharing the warm-compress + lid-hygiene foundation but diverging in specific therapy: anterior bacterial → topical antibiotic; Demodex → lotilaner; chronic chalazion → intralesional steroid or I&C; stye → conservative + topical antibiotic if blepharitis present. The over-arching guardrail is sebaceous-carcinoma masquerade in recurrent same-site chalazia and the orbital-cellulitis route-out (AAO PPP Blepharitis 2023).

Inputs
0
Actions
0
Advance rule
Set
Advance when

bundle frame + masquerade and orbital-cellulitis route-out noted

Patient inputs (11)

Ocular rosacea, seborrhoeic dermatitis, and atopic disease drive chronic blepharitis; co-manage skin disease via derm engines (AAO PPP Blepharitis 2023)

Blepharitis-MGD is the dominant driver of evaporative DED; co-engage ophtho.dry-eye-disease.core.v1 (TFOS DEWS II)

Tender + red + pointing pustule = stye (acute); painless + firm nodule = chalazion (chronic); both warrant warm compress foundation (AAO PPP Blepharitis 2023)

Slit-lamp inspection of lid margin (anterior vs posterior signs; cylindrical collarettes; lid-margin telangiectasia; orifice plugging) drives subtype assignment (AAO PPP Blepharitis 2023; SATURN-1 PMID 35965392)

Recurrent same-site lesion, madarosis, distorted lid architecture, ulceration, induration → biopsy to exclude sebaceous / basal-cell / squamous-cell carcinoma (AAO PPP Blepharitis 2023)

Proptosis + pain with eye movement + ophthalmoplegia + decreased vision → orbital cellulitis (post-septal infection) — route OUT to ophtho.orbital-cellulitis.core.v1 emergently

Collarette grade (0/1/>1) per SATURN scale guides lotilaner candidacy and post-treatment monitoring (SATURN-1 PMID 35965392; SATURN-2 PMID 37285925)

Contact-lens wear, eyelash extensions, mascara residue exacerbate lid-margin disease; counsel pause / replacement (AAO PPP Blepharitis 2023)

Meibomian gland expression yields normal clear oil vs turbid/granular/inspissated material — quantifies MGD severity and drives in-office procedure decisions (AAO PPP Blepharitis 2023)

Doxycycline contraindicated in pregnancy / under age 8 — gates the anti-inflammatory adjunct (AAO PPP Blepharitis 2023)

Intralesional triamcinolone risks skin hypopigmentation + atrophy more visibly in darker Fitzpatrick skin types — counsel and consider incision-and-curettage preferentially (AAO PPP Blepharitis 2023)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningorbital_cellulitis_red_flags
    Lid swelling + proptosis + pain on eye movement + ophthalmoplegia + decreased vision + fever
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresebaceous_carcinoma_masquerade
    Recurrent same-site chalazion in older adult + madarosis / distorted lid / induration / atypical features
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveredoxycycline_contraindicated_pregnancy_or_pediatric
    Patient pregnant / breastfeeding / under age 8 considered for oral doxycycline
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatedemodex_blepharitis_collarettes
    Cylindrical collarettes at lash base on slit-lamp — diagnostic for Demodex
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateocular_rosacea_refractory_blepharitis
    Refractory posterior MGD / blepharitis in a patient with facial rosacea features
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatechronic_chalazion_refractory_to_conservative
    Chalazion persisting beyond 4-6 weeks of warm compress + lid hygiene
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

Blepharitis + stye + chalazion — combined outpatient ladder (AAO PPP 2023 + SATURN trials)
axis: blepharitis_stye_chalazion_combined_ladderstep 1 - Step 1 — Foundation: warm compress + lid hygiene + omega-3 (all three disorders)
Selected step "Step 1 — Foundation: warm compress + lid hygiene + omega-3 (all three disorders)" — All patients with blepharitis, stye, or chalazion — the substrate beneath every higher tier
  • warm_compress_5_to_10_min_QID
    first line
    thermotherapy
    AAO PPP Blepharitis 2023 — warm compress softens meibum and inspissated material; foundation for blepharitis + stye + chalazion.
  • lid_hygiene_scrub_or_dilute_baby_shampoo
    first line
    lid_hygiene
    AAO PPP Blepharitis 2023 — daily lid-margin cleaning reduces bacterial / lipase burden and scurf.
  • omega_3_for_mgd
    add on
    nutritional
    triggers: posterior_mgd_dominant
    AAO PPP Blepharitis 2023 — conditional benefit for evaporative MGD; DREAM trial neutral but TFOS DEWS II retains conditional support.

outpatient playbook — drug actions (5)

  1. 1. warm compress + lid hygiene + omega-3 (foundation)
    5-10 min q.i.d. • non-drug • daily
    trigger: Any blepharitis / stye / chalazion (AAO PPP Blepharitis 2023)
    Step 1 substrate beneath every higher tier
  2. 2. erythromycin ophthalmic ointment qhs (anterior blepharitis)
    rxcui 374382
    0.5% • topical (eyelid margin) • qhs x1-2 wk
    trigger: Anterior staphylococcal blepharitis (AAO PPP Blepharitis 2023)
    First-line topical antibiotic; bedtime application
  3. 3. doxycycline 50-100 mg BID (refractory MGD / ocular rosacea)
    rxcui 3640
    50-100 mg • PO • BID 2-12 wk
    trigger: Refractory MGD / ocular rosacea / recurrent chalazia (AAO PPP Blepharitis 2023)
    Anti-inflammatory + anti-lipase; pregnancy + age-<8 contraindication
  4. 4. lotilaner ophthalmic 0.25% BID x6 wk (Demodex blepharitis)
    rxcui 1998841
    0.25% • topical (ophthalmic) • BID x6 wk
    trigger: Cylindrical collarettes diagnostic for Demodex (SATURN-1/2 PMID 35965392 / 37285925)
    Pooled collarette grade 0 49.8% vs 9.9%; mite eradication 60.2% vs 16.1%
  5. 5. intralesional triamcinolone 40 mg/mL 0.1-0.2 mL (refractory chalazion)
    rxcui 10761
    4-8 mg • intralesional transconjunctival • single (repeat in 4-6 wk if needed)
    trigger: Chalazion persisting >4-6 wk (AAO PPP Blepharitis 2023)
    ~70% resolution at 4-6 wk; counsel skin hypopigmentation in darker Fitzpatrick

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Chronic lid-margin crusting / scurf / burning / itching with foamy tears or red lid margins — anterior + posterior blepharitis (AAO PPP Blepharitis 2023); Cylindrical waxy collarettes encircling the lash base on slit-lamp — diagnostic for Demodex blepharitis (SATURN-1 PMID 35965392; SATURN-2 PMID 37285925); Acutely tender, red, focal lid swelling with pointing pustule — external (gland-of-Zeis) or internal (meibomian-gland) hordeolum / stye.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Blepharitis, hordeolum (stye), and chalazion** (ophtho.blepharitis-stye-chalazion.core.v1).
Phenotype framing: Terminal differential: anterior blepharitis (Staphylococcal vs seborrhoeic) vs posterior MGD vs Demodex blepharitis (collarettes pivot) vs hordeolum/stye (acute tender) vs chalazion (chronic painless) vs sebaceous carcinoma (recurrent + atypical → biopsy) vs basal-cell / squamous-cell lid carcinoma vs preseptal/orbital cellulitis (route OUT) vs pyogenic granuloma (post-chalazion incision) vs trichiasis-driven mechanical irritation (AAO PPP Blepharitis 2023).
Scope: Frame as a three-disorder common-outpatient bundle (blepharitis / stye / chalazion) sharing the warm-compress + lid-hygiene foundation but diverging in specific therapy: anterior bacterial → topical antibiotic; Demodex → lotilaner; chronic chalazion → intralesional steroid or I&C; stye → conservative + topical antibiotic if blepharitis present. The over-arching guardrail is sebaceous-carcinoma masquerade in recurrent same-site chalazia and the orbital-cellulitis route-out (AAO PPP Blepharitis 2023).

No severity triggers fired against current inputs.

Plan

Regimen axis: **Blepharitis + stye + chalazion — combined outpatient ladder (AAO PPP 2023 + SATURN trials)** — step "Step 1 — Foundation: warm compress + lid hygiene + omega-3 (all three disorders)".
1. warm_compress_5_to_10_min_QID (thermotherapy, first line) — AAO PPP Blepharitis 2023 — warm compress softens meibum and inspissated material; foundation for blepharitis + stye + chalazion.
2. lid_hygiene_scrub_or_dilute_baby_shampoo (lid_hygiene, first line) — AAO PPP Blepharitis 2023 — daily lid-margin cleaning reduces bacterial / lipase burden and scurf.
3. omega_3_for_mgd (nutritional, add on) — AAO PPP Blepharitis 2023 — conditional benefit for evaporative MGD; DREAM trial neutral but TFOS DEWS II retains conditional support.

Setting playbook (outpatient) — Distinguish anterior bacterial / posterior MGD / Demodex blepharitis vs stye vs chalazion; deliver warm-compress + lid-hygiene foundation; layer subtype-specific therapy (topical antibiotic / oral doxycycline / lotilaner / intralesional triamcinolone or I&C); biopsy recurrent atypical lid lesions; route orbital extension OUT (AAO PPP Blepharitis 2023; SATURN PMID 35965392 / 37285925 / 39873946)
4. warm compress + lid hygiene + omega-3 (foundation) 5-10 min q.i.d. non-drug daily — Any blepharitis / stye / chalazion (AAO PPP Blepharitis 2023) (Step 1 substrate beneath every higher tier)
5. erythromycin ophthalmic ointment qhs (anterior blepharitis) 0.5% topical (eyelid margin) qhs x1-2 wk — Anterior staphylococcal blepharitis (AAO PPP Blepharitis 2023) (First-line topical antibiotic; bedtime application)
6. doxycycline 50-100 mg BID (refractory MGD / ocular rosacea) 50-100 mg PO BID 2-12 wk — Refractory MGD / ocular rosacea / recurrent chalazia (AAO PPP Blepharitis 2023) (Anti-inflammatory + anti-lipase; pregnancy + age-<8 contraindication)
7. lotilaner ophthalmic 0.25% BID x6 wk (Demodex blepharitis) 0.25% topical (ophthalmic) BID x6 wk — Cylindrical collarettes diagnostic for Demodex (SATURN-1/2 PMID 35965392 / 37285925) (Pooled collarette grade 0 49.8% vs 9.9%; mite eradication 60.2% vs 16.1%)
8. intralesional triamcinolone 40 mg/mL 0.1-0.2 mL (refractory chalazion) 4-8 mg intralesional transconjunctival single (repeat in 4-6 wk if needed) — Chalazion persisting >4-6 wk (AAO PPP Blepharitis 2023) (~70% resolution at 4-6 wk; counsel skin hypopigmentation in darker Fitzpatrick)

Non-pharmacologic actions:
- Transconjunctival incision-and-curettage for refractory chalazion (AAO PPP Blepharitis 2023)
- In-office MGD thermal pulsation / IPL for refractory posterior MGD
- Biopsy threshold low for recurrent same-site or atypical lid lesion (sebaceous carcinoma)
- Counsel cessation of eyelash extensions / mascara residue contributing to blepharitis
- Co-engage ophtho.dry-eye-disease.core.v1 for MGD-driven evaporative DED
- Co-engage derm engines for rosacea / seborrhoeic / atopic comorbidity

AVOID / contraindication checks:
- Doxycycline contraindicated in pregnancy breastfeeding and children under 8 (AAO PPP Blepharitis 2023)
- Doxycycline photosensitivity oesophagitis counsel take upright with water (AAO PPP Blepharitis 2023)
- Intralesional triamcinolone skin hypopigmentation and atrophy counsel darker Fitzpatrick (AAO PPP Blepharitis 2023)
- Never squeeze a pointing stye counsel warm compress (AAO PPP Blepharitis 2023)
- Recurrent same site chalazion older adult biopsy for sebaceous carcinoma (the masquerader; high mortality if missed)
- Orbital extension proptosis motility pain route OUT to ophtho.orbital cellulitis.core.v1

Monitoring

Regimen monitoring:
- lid margin signs and symptom score at 4 to 6 weeks per step (AAO PPP Blepharitis 2023)
- Demodex collarette grade recheck at 6 weeks on lotilaner (SATURN-1 PMID 35965392; SATURN-2 PMID 37285925)
- chalazion resolution recheck at 4 to 6 weeks after intralesional steroid (AAO PPP Blepharitis 2023)
- adherence and lid hygiene technique every visit (AAO PPP Blepharitis 2023)
- biopsy threshold low for recurrent atypical lid lesion (sebaceous carcinoma surveillance)

Setting (outpatient) monitoring:
- Lid-margin signs + symptom score at 4-6 weeks per intervention (AAO PPP Blepharitis 2023)
- Demodex collarette grade re-check at 6 weeks on lotilaner (SATURN-1/2)
- Chalazion resolution at 4-6 weeks after intralesional steroid
- Adherence audit + lid-hygiene technique every visit

Follow-up plan: Chronic-disease maintenance for blepharitis-MGD: lifelong lid hygiene + warm compress + omega-3; episodic flare control. Counsel patients that blepharitis is a chronic condition; reinforce daily routine. Co-manage rosacea / atopic / seborrhoeic skin disease via derm engines. Co-manage evaporative DED via ophtho.dry-eye-disease.core.v1. Repeat biopsy threshold for any recurrent atypical lesion (AAO PPP Blepharitis 2023).
- Close-out criterion: chronic-disease maintenance plan + co-management documented

Monitoring phase: Re-examine at 4-6 weeks per intervention: blepharitis on topical antibiotic / lotilaner / doxycycline; chalazion conservatively (often resolves spontaneously by 6 wk); after intralesional steroid (re-injection at 4-6 wk if persistent). Adherence audit and lid-hygiene technique check every visit (AAO PPP Blepharitis 2023).

Disposition

Current setting: outpatient — Distinguish anterior bacterial / posterior MGD / Demodex blepharitis vs stye vs chalazion; deliver warm-compress + lid-hygiene foundation; layer subtype-specific therapy (topical antibiotic / oral doxycycline / lotilaner / intralesional triamcinolone or I&C); biopsy recurrent atypical lid lesions; route orbital extension OUT (AAO PPP Blepharitis 2023; SATURN PMID 35965392 / 37285925 / 39873946)

Disposition criteria:
- Continue outpatient ophthalmology / optometry co-management (AAO PPP Blepharitis 2023)
- Oculoplastics referral for biopsy or definitive surgical management
- Cornea referral for chronic blepharitis with corneal involvement

Escalation triggers (move to higher acuity):
- Orbital extension (proptosis + motility restriction + pain on eye movement + decreased vision + fever) → ophtho.orbital-cellulitis.core.v1 same-day
- Preseptal cellulitis (lid swelling alone) → ophtho.preseptal-cellulitis.core.v1
- Recurrent same-site chalazion in older adult → oculoplastics biopsy for sebaceous carcinoma
- Suspected BCC / SCC / pigmented atypical lid lesion → oculoplastics biopsy

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Lid swelling + proptosis + pain on eye movement + ophthalmoplegia + decreased vision + fever
- [SEVERE] Recurrent same-site chalazion in older adult + madarosis / distorted lid / induration / atypical features
- [SEVERE] Patient pregnant / breastfeeding / under age 8 considered for oral doxycycline

Citations

- AAO Preferred Practice Pattern Blepharitis 2023 cycle + SATURN-1 (Yeu et al, Cornea 2022, PMID 35965392) + SATURN-2 (Gaddie et al, Ophthalmology 2023, PMID 37285925) + pooled SATURN-1/-2 (Yeu et al, Ophthalmol Ther 2025, PMID 39873946) [PMID:35965392](https://pubmed.ncbi.nlm.nih.gov/35965392/)
- Cited evidence (PMID 37285925) [PMID:37285925](https://pubmed.ncbi.nlm.nih.gov/37285925/)
- Cited evidence (PMID 39873946) [PMID:39873946](https://pubmed.ncbi.nlm.nih.gov/39873946/)

Last reconciled with current guidelines: 2026-05-26.
References
  • AAO Preferred Practice Pattern Blepharitis 2023 cycle + SATURN-1 (Yeu et al, Cornea 2022, PMID 35965392) + SATURN-2 (Gaddie et al, Ophthalmology 2023, PMID 37285925) + pooled SATURN-1/-2 (Yeu et al, Ophthalmol Ther 2025, PMID 39873946) — PMID:35965392
  • Cited evidence (PMID 37285925) — PMID:37285925
  • Cited evidence (PMID 39873946) — PMID:39873946